David Kupfer, Ph.D. A Mentor and a Scientist

References

• Bernstein L., Deapen D., Cerhan J. R., Schwartz S. M., Liff J., McGann-Maloney E., Perlman J. A., Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst 1999; 91: 1654–1662, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Blizard D., Sueyoshi T., Negishi M., Dehal S. S., Kupfer D. Mechanism of induction of cytochrome P450 enzymes by the proestrogenic endocrine disruptor pesticide methoxychlor: interactions of methoxychlor metabolites with the constitutive androstane receptor system. Drug Metab. Dispos 2001; 29: 781–785, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Borgna J.-L., Rochefort H. Hydroxylated metabolites of tamoxifen are formed in situ and bound to estrogen receptor in target tissue. J. Biol. Chem 1981; 256: 859–868, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bulger W. H., Muccitelli R. M., Kupfer D. Studies on the in vivo and in vitro estrogenic activities of methoxychlor and its metabolites. Biochem. Pharmacol 1978; 27: 2417–2423, Role of hepatic mono-oxygenases in methoxychlor activation[INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bulger W. H., Temple J. E., Kupfer D. Covalent binding of 14C-methoxychlor metabolites to rat liver components. Toxicol. Appl. Pharmacol 1983; 68: 367–374, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bulger W. H., Kupfer D. Characteristics of monooxygenase-mediated covalent binding of methoxychlor in human and rat liver microsomes. Drug Metab. Dispos 1989; 17: 487–494, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Coezy E., Borgna J. L., Rochefort H. Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1988; 42: 317–323, [CSA]
   Google Scholar
• Crewe H. K., Ellis S. W., Lennard M. S., Tucker G. T. Variable contribution of cytochrome P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol 1997; 53: 171–178, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cummings A. M., Luskey J. Effect of methoxychlor on ovarian steroidogenesis: role in early pregnancy loss. Reprod. Toxicol 1993; 7: 17–23, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dehal S. S., Kupfer D. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Drug Metab. Dispos 1994; 22: 937–946, Dual pathways involving novel ortho ring-hydroxylation by CYP2B[INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dehal S. S., Kupfer D. Evidence that the catechols 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res 1996; 56: 1283–1290, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dehal S. S., Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997; 57: 3402–3406, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dehal S. S., Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (Droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos 1999; 27: 681–688, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dehal and Kupfer (unpublished)
   Google Scholar
• Fan P. W., Zhang F., Bolton J. L. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol 2000; 13: 45–52, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Foster A. B., Griggs L. J., Jarman M., vanMaanen M. S., Schulten H.-R. Metabolism of tamoxifen by rat liver microsomes: formation of the oxide, a new metabolite. Biochem. Pharmacol 1980; 29: 1977–1979, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Furr B. J. A., Jordan V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. &Ther 1984; 25: 127–205, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gaido K. W., Maness S. C., McDonnell D. P., Dehal S. S., Kupfer D., Safe S. Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies. Mol. Pharmacol 2000; 58: 852–858, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gray L. E., Jr., Ostby J. S., Farrell J. M., Sigmon E. R., Goldman J. M. Methoxychlor induces estrogen-like alterations of behavior and the reproductive tract in the female rat and hamster: effect on sex behavior, running wheel activity and uterine morphology. Toxicol. Appl. Pharmacol 1988; 96: 525–540, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hazai E., Gagne P. V., Kupfer D. Glucuronidation of the oxidative cytochrome P450-mediated phenolic metabolites of the endocrine disruptor pesticide: methoxychlor by human hepatic UDP-glucuronosyltransferases. Drug Metab. Dispos 2004; 32: 742–751, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hu Y., Kupfer D. Metabolism of the endocrine disruptor pesticide methoxychlor by human P450s: pathways involving a novel catechol metabolite. Drug Metab. Dispos 2002; 30: 1035–1042, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hu Y., Krausz K., Gelboin H. V., Kupfer D. CYP2C subfamily, primarily CYP2C9, catalyzes the enantioselective demethylation of the endocrine disruptor pesticide methoxychlor in human liver microsomes: use of inhibitory monoclonal antibodies in P450 identification. Xenobiotica 2004; 34: 117–132, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hu Y., Dehal S. S., Hynd G., Jones G. B., Kupfer D. CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes. Xenobiotica 2003; 33: 141–151, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., Berthou F. Identification of the cytochrome P-450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol 1991; 41: 1911–1919, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jordan V. C. Tamoxifen: a most unlikely pioneering medicine. Nature Rev 2003; 2: 205–213, [CSA]
   Web of Science ®Google Scholar
• Kapoor I. P., Metcalf R. L., Nystrom R. F., Sangha G. K. Comparative metabolism of methoxychlor, methiochlor, and DDT in mouse, insects, and in a model ecosystem. J. Agric. Food Chem 1970; 18: 1145–1152, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kupfer D. The covalent binding of tamoxifen to proteins and DNA. Tamoxifen: Beyond the Antiestrogen, J. A. Kellen. Birkhauser, Boston 1996; 201–230
   Google Scholar
• Kupfer D., Bulger W. H., Theoharides A. D. Metabolism of methoxychlor by hepatic P-450 monooxygenases in rat and human. I. Characterization of a novel catechol metabolite. Chem. Res. Toxicol 1990; 3: 8–16, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kupfer D., Mani C., Lee C. A., Rifkind A. B. Induction of tamoxifen-4-hydroxylation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), b-naphthoflavone (bNF), and phenobarbital (PB) in avian liver: identification of P450 TCDDAA as catalyst of 4-hydroxylation induced by TCDD and bNF. Cancer Res 1994; 53: 3140–3144, [CSA]
   Google Scholar
• Li H.-C., Dehal S. S., Kupfer D. Induction of the hepatic CYP2B and CYP3A enzymes by the proestrogenic pesticide methoxychlor and DDT in the rat. J. Biochem. Molec. Toxicol 1995; 10: 51–61, Effect on methoxychlor metabolism[CSA]
   Web of Science ®Google Scholar
• Li H.-C., Kupfer D. Mechanism of induction of rat hepatic CYP2B and 3A by the pesticide methoxychlor. J. Biochem. Molec. Toxicol 1998; 12: 315–323, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lim C. K., Yuan Z.-X., Lamb J.H., White I. N. H., De Matteis F., Smith L. L. A comparative study of tamoxifen metabolism in female rats, mouse and human liver microsmes. Carcinogenesis 1994; 15: 589–593, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Malet C., Compel A., Spritzer P., Bricout N., Yaneva H., Mowszowicz I., Kuttenn F., Mayvais-Jarvis P. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cancer cells in culture. Cancer Res 1988; 48: 7193–7199, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mani C., Gelboin H. V., Park S. S., Pierce R., Parkinson A., Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. Drug Metab. Dispos 1993a; 21: 645–656, I. Cytochrome P-450-catalyzed N‐demethylation and 4-hydroxylation[INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mani C., Hodgson E., Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. Drug Metab. Dispos 1993b; 21: 657–661, II. Flavin-containing monooxygenases mediated N-oxidation[INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mani C., Kupfer D. Cytochrome P-450 mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 1991; 51: 6052–6058, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mani C., Pierce R., Parkinson A., Kupfer D. Involvement of cytochrome P-4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15: 2715–2720, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McCague R., Seago A. Aspects of metabolism of tamoxifen by rat liver microsomes. Biochem. Pharmacol 1986; 35: 827–834, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Metcalf R. L. The Future of Insecticides. R. L. Metcalf, J. J. McKelevey. Wiley, New York 1976; 223–285
   Google Scholar
• Osterhout J. M., Struck R. F., Nelson J. A. Estrogenic activities of methoxychlor metabolites. Biochem. Pharmacol 1981; 30: 2869–2871, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Regan R. M., Cisneros A., England G. M., MacGregor J. L., Muenzner H. D., Assikis V. J., Bilimoria M. M., Piette M., Dragan Y. P., Pitot H. C. Effects of antiestrogens tamoxifen, toremifene, and ICI 182, 780 in endometrial cancer growth. J. Natl. Cancer Inst 1998; 90: 1552–1558, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Parte P., Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab. Dispos 2005; 33: 1446–1452, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pathak D. N., Pongracz K., Bodell W. J. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 1995; 16: 11–15, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Phillips D. H., Carmichael P. L., Hewer A., Kole K. J., Poon G. K. A-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 1994; 54: 5518–5522, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Poon G. K., Chui Y. C., McCague R., Lonning P. E., Feng R., Rowlands M. G., Jarman M. Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos 1993; 21: 1119–1124, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Poon G. K., Walter B., Lonning P. E., Holten M. N., McCague R. Identification of tamoxifen metabolites in human hepG2 cell line, human liver homogenate and patients on long-term therapy for breast cancer. Drug Metab. Dispos 1995; 23: 377–382, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Randernath K., Moorthy B., Mabon N., Sriram P. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 1994; 15: 2087–2094, [CSA]
   PubMed Web of Science ®Google Scholar
• Reunitz P. C. Rabbit hepatic microsomal O-demethylation of chlorotrianisene. Drug Metab. Dispos 1978; 6: 478–483, [CSA]
   Google Scholar
• Reunitz P. C., Bagley J. R., Pape C. W. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab. Dispos 1984; 12: 478–483, [CSA]
   PubMed Web of Science ®Google Scholar
• Reunitz P. C., Toledo M. M. Chemical and biochemical characteristics of O-demethylation of chlorotrianisene in the rat. Biochem. Pharmacol 1981; 30: 2203–2207, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Smith L. L., Brown K., Carthew P., Lim C. K., Martin E. A., Styles J., White I. N. H. Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit. Rev. Toxicol 2000; 30: 571–594, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stresser D. M., Kupfer D. Catalytic characteristics of CYP3A4: Requirements for phenolic function in orthohydroxylation of estradiol and O-demethylated methoxychlor. Biochemistry 1997; 36: 2203–2210, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sueyoshi H., Kawamoto T., Zelko I., Honkakaski P., Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem 1991; 274: 6043–6046, [CROSSREF], [CSA]
   Google Scholar
• Sueyoshi H., Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Ann. Rev. Pharmacol. Toxicol 2001; 41: 123–143, [CSA]
   PubMed Web of Science ®Google Scholar
• Vancutsem P. M., Lazarus P., Williams G. M. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 1993; 54: 3864–3867, [CSA]
   Web of Science ®Google Scholar
• Williams G. M., Latropoulos M. J., Djordjevic M. W., Kaltenberg O. P. The triphenylethylene drug tamoxifen is a strong carcinogen in the rat. Carcinogenesis 1993; 14: 315–317, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhang F., Fan P. W., Lie X., Shen L., vanBreeman R.B., Bolton J.L. Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone. Chem. Res. Toxicol 2000; 13: 53–62, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhou L. X., Dehal S. S., Kufper D., Morrell S., McKenzie B. A., Eccleston E. D., Jr., Holtzman J. L. Cytochrome P450 catalyzed covalent binding of methoxychlor to rat hepatic, microsomal iodothyronine 5′-monodeiodinase, type I: does exposure to methoxychlor disrupt thyroid hormone metabolism?. Arch. Biochem. Biophys 1995; 322: 390–394, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar